The agency takes other steps to make COVID-19 tests more available.
FDA cleared two new coronavirus disease (COVID-19) tests via Emergency Use Authorization.
FDA Commissioner Stephen M. Hahn, MD, also outlined other ways the agency is working to get more tests available.
Related: Top 3 Things to Know About Coronavirus Treatments
The agency expedited approval of Panther Fusion SARS-COV-2 Assay (Hologic), and Laboratory Corporation of America (LabCorp) for its COVID-19 RT-PCR test.
“Staff at FDA have been working nonstop to expedite the review and authorization of diagnostics during this public health emergency,” Hahn says in a press release. “Our device center has been in continual contact with the medical device community, in particular diagnostic developers, since January -- providing technical assistance to test developers to help facilitate the availability and distribution of tests so that health care professionals can accurately detect the COVID-19 virus.”
More than 40 labs have notified FDA that they are testing or intend to begin testing COVID-19 assays, Hahn added.
Related: FDA, FTC warn suppliers of fraudulent COVID-19 products
In addition, FDA’s new policy will allow states to take responsibility for tests developed and used by laboratories in their states.
“States can set up a system in which they take responsibility for authorizing such tests and the laboratories will not engage with the FDA,” Hahn says in a separate press release.
FDA’s updated policy also provides recommendations for test developers that may wish to develop serological tests for use during the coronavirus outbreak.
“Serological tests measure the amount of antibodies or proteins present in the blood when the body is responding to a specific infection. We recognize that serology tests are less complex than molecular tests and are solely used to identify antibodies, which limits their effectiveness for diagnosis; however, as stated in the updated guidance, the FDA does not intend to object to the distribution and use of serology tests to identify antibodies to SARS-CoV-2 where the test has been validated, notification is provided to the FDA, and warning statements are included with the tests…” Hahn says.
FDA has engaged with more than 100 test developers since the end of January, providing templates and advice about the Emergency Use Authorization process.
“More than 80 developers have sought our assistance with development and validation of tests they plan to bring through the EUA process. We’ve granted multiple diagnostic EUAs during this outbreak,” he says said.
Read more: More Ranitidine Recalled, Plus Another Big Drug Recall
What's On the Mind of Eric Hunter? The Network of CareOregon and the Members They ServeMay 10th 2023
This month’s episode of the "What's On Your Mind" podcast series features Eric Hunter, president and CEO of CareOregon. MHE Managing Editor Peter Wehrwein, Editor Briana Contreras and Hunter discuss Medicaid redetermination and merger of CareOregon and the California-based insurer, SCAN Group.
The Don'ts of Kicking Off Your Digital Health StartupMay 5th 2023
This month's episode of Tuning In to the C-Suite features Erica Jain, CEO & co-founder of digital health company, Healthie. In this discussion, Jain shared some of the challenges or things to avoid when creating a digital health startup, based on her journey with starting Healthie in 2016. She also addressed some best practices and tools that can help those working toward a digital health startup.
The Risk of Developing Childhood Asthma Is Lower if a Child Was Not Infected With RSV as an InfantJune 1st 2023
Understanding whether the prevention of RSV infection during infancy can reduce the risk of childhood asthma is key to designing successful and preventive strategies, preventing long-term childhood respiratory morbidity, and outlining healthcare policy measures.
2 Clarke Drive
Cranbury, NJ 08512